Global Microbial Therapeutic market is valued approximately USD 179.28 million in 2019 and is anticipated to grow with a healthy growth rate of more than 8.7 % over the forecast period 2020-2027. A microbe is a microscopic living organism, such as a bacteria, yeast, or fungus. Microbial products are produced by microbes and are mainly utilized for producing cheese, wine , vinegar and bread. Medicinal microbiology includes production of enzymes, antibiotics, nutrients etc. The driving factors for microbial products are increasing prevalence of diseases which has led to the adoption of microbial technology for production of enzymes, vitamins and nutrients. According to the World Health Organization, chronic disease prevalence is slated to increase 57% by 2020-end which is about 44% currently. As the global geriatric population increases, prevalence of conditions such as diabetes, cardiovascular problems, cancers and asthma are bound to rise. So , pharmaceutical companies are accelerating their research to develop effective treatments by using microbial products. However, low quality producers operating from unknown locations impedes the growth of the market over the forecast period of 2020-2027. Also, Opportunity is increasing demand for high quality reagents for producing medicines so the adoption & demand for Microbial Therapeutic Products is likely to increase.

The regional analysis of global Microbial Therapeutic Product is considered for the key regions such as Asia Pacific, North America, Europe, Latin America and Rest of the World. US is the leading/significant region across the world in terms of market share owing to the increasing expenditure on healthcare and per capita consumption of microbial products. Whereas, Europe is also anticipated to exhibit highest growth rate / CAGR over the forecast period 2020-2027. Factors such as rising disposable income and rising consumption patterns would create lucrative growth prospects for the Microbial Therapeutic Products across Europe.

Major market player included in this report are:
Amgen Inc.
Merck & Co.,Inc.
Valent BioSciences Corp.
GlaxoSmithKline plc
Pfizer Inc.
bioMrieux SA
Ajinomoto Co.Inc.
Sanofi S.A
Novartis AG
NovaDigm Therapeutics

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Source:
Bacteria
Fungi

By Application:
Metabolic Disorders
Haematological Disorders
Oncology
Immunological Disorders

By End User:
Hospitals
Pharmaceuticals & Biopharmaceutical Companies
Research & Academic Institutions

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year 2017, 2018
Base year 2019
Forecast period 2020 to 2027

Target Audience of the Global Microbial Therapeutic Products in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors